Longitudinal SARS-CoV-2 Immune Responses Post-Vaccination

In December 2020, we established a prospective longitudinal study in Vancouver, Canada, to examine SARS-CoV-2 specific humoral immune responses following vaccination with BNT162b2 (Comirnaty; BioNTech/Pfizer) or mRNA-1273 (Spikevax; Moderna) in a cohort of adults aged 24-98 years [described in (25 (link), 26 (link))]. Serum and plasma were collected longitudinally up to 6 months following the third dose (Figure 1A). At each visit, serum was tested for the presence of SARS-CoV-2 anti-nucleocapsid (N) antibodies, which indicate seroconversion following infection, using the Elecsys Anti-SARS-CoV-2 assay on a Cobas e601 module analyzer (Roche Diagnostics). In addition to the case participant, immune measures from a comparison group of 124 participants of this cohort, who remained anti-N seronegative up until at least one month post-third vaccine dose, are included for context.

Free full text: Click here

Lapointe H.R., Mwimanzi F., Cheung P.K., Sang Y., Yaseen F., Kalikawe R., Datwani S., Waterworth R., Umviligihozo G., Ennis S., Young L., Dong W., Kirkby D., Burns L., Leung V., Holmes D.T., DeMarco M.L., Simons J., Matic N., Montaner J.S., Brumme C.J., Prystajecky N., Niikura M., Lowe C.F., Romney M.G., Brockman M.A, & Brumme Z.L. (2022). Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccination. Frontiers in Immunology, 13, 947021.

Publication 2022

Spikevax Cobas e601 module analyzer

Adults Antibodies Assay Bnt162b2 Comirnaty Diagnostics Humoral immune responses Infection Mrna 1273 Nucleocapsid Plasma Sars Sars cov 2 Serum Spikevax Vaccination Vaccine

Corresponding Organization : Simon Fraser University

Other organizations : St. Paul's Hospital, Providence Health Care, University of British Columbia, BC Centre for Disease Control

Top 5 similar protocols

Variable analysis

independent variables

Vaccination with BNT162b2 (Comirnaty; BioNTech/Pfizer) or mRNA-1273 (Spikevax; Moderna)

dependent variables

SARS-CoV-2 specific humoral immune responses
Presence of SARS-CoV-2 anti-nucleocapsid (N) antibodies

control variables

Participants aged 24-98 years

controls

Comparison group of 124 participants who remained anti-N seronegative up until at least one month post-third vaccine dose

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!